Clinical Trial Update: Sustained Release Formulation of Somatropin (rDNA Origin)for Injection [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial update for a sustained-release somatropin formulation (rDNA origin) for injection in growth hormone deficiency. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Growth Hormone Deficiency

Drugs mentioned

• Somatropin (rDNA origin) for injection (somatropin)

Snippet

Sponsor: BioPartners GmbH | Conditions: Growth Hormone Deficiency | Phase 2, Phase 3 | Status: COMPLETED